Seaport Therapeutics
Update in progressSPTX (NasdaqGS)
- Company RatingNeutralCompany RatingCombines sentiment and sustainability signals into an overall assessment of the company.Great · Good · Neutral · At Risk · Poor
- SectorHealthcare
- IndustryBiotechnology
Seaport Therapeutics is a clinical-stage biopharma developing new medicines for depression, anxiety, and other neuropsychiatric disorders. Using its Glyph platform, it advances a therapeutic pipeline, including GlyphAllo (SPT-300), an oral prodrug of allopregnanolone, and GlyphAgo (SPT-320), an oral prodrug of agomelatine. Founded in 2024, the company is based in Boston, MA.
Company score
- Sentiment
- 0.48
- SentimentMeasures the overall tone of recent coverage and discussion about the company.−10 negative · 0 neutral · +10 positive
- Environment
- 0.00
- EnvironmentAssesses the company’s environmental impact, risks, and sustainability practices.−10 negative · 0 neutral · +10 positive
- Social
- 0.53
- Governance
- 0.16
- GovernanceAssesses leadership, accountability, transparency, and business ethics.−10 negative · 0 neutral · +10 positive
- Sustainability
- 0.19
- SustainabilityCombines environmental, social, and governance signals into an overall sustainability score.−10 negative · 0 neutral · +10 positive
- Impact Score
- 0.34
- Impact ScoreCombines sentiment and sustainability performance into an assessment of the company’s overall impact.−10 negative · 0 neutral · +10 positive
Company
- MarketNasdaqGS (NMS)
- LocationUnited States
- CEOMs. Daphne Zohar
- Founded2024
- Employees58
- Websitewww.seaporttx.com